JMP Securities Maintains Allogene Therapeutics(ALLO.US) With Hold Rating
JMP Securities analyst Reni Benjamin maintains $Allogene Therapeutics(ALLO.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 35.5% and a total average return of -6.
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of James Hardie Industries plc (NYSE:JHX) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.James Hardie Industries posted adjuste
Allogene Therapeutics Shares Jump 10% on Share Purchases by Chairman, CEO
By Denny Jacob Allogene Therapeutics shares jumped 10% on Tuesday after company insiders bought up shares, often an indication of confidence by leadership. Shares were trading around $2.83. The stoc
Insider Trading: Allogene Therapeutics' Insider Buys Shares Worth $5M
ASTS, ALLO and CMCM Are Among Premarket Gainers
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of Larimar Therapeutics, Inc.. (NASDAQ:LRMR) rose sharply in today's pre-market trading after the company announced that the FDA removed the partial clinical hold previously placed on the nomla
Allogene Therapeutics Is Maintained at Outperform by Oppenheimer
Allogene Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Allogene : Oppenheimer Cuts Target Price to $13 From $14
Express News | Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $13
Analysts Are Bullish on These Healthcare Stocks: Savara (SVRA), Allogene Therapeutics (ALLO)
Allogene Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Allogene Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Allogene Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $9 From $10
Truist Securities Maintains Buy on Allogene Therapeutics, Maintains $17 Price Target
Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics with a Buy and maintains $17 price target.
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.Arcutis Biotherapeutics
Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), Allogene Therapeutics (ALLO)
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday.Shares of DLocal Limited (NASDAQ:DLO) fell sharply in today's pre-market trading after
Express News | Allogene Therapeutics Files For Offering Of Up To 37.93M Shares Of Common Stock
Express News | Allogene Therapeutics Inc Files for Offering of up to 37.93 Mln of Common Stock - SEC Filing
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Generation Bio (GBIO)
Express News | Allogene Therapeutics Inc : B. Riley Cuts Target Price to $7 From $10